Adnan I. Qureshi, MD; Wei Huang, MA; Iryna Lobanova, MD; et al.
free access
has audio
JAMA Neurol. 2020;77(11):1355-1365. doi:10.1001/jamaneurol.2020.3075
This secondary analysis of a randomized clinical trial evaluates the differential outcomes of intensive vs standard systolic blood pressure reduction in patients with intracerebral hemorrhage and initial systolic blood pressure of 220 mm Hg or more vs less than 220 mm Hg.
-
Podcast:
Intensive Systolic Blood Pressure Reduction in Intracerebral Hemorrhage
Alexander E. Merkler, MD; Neal S. Parikh, MD, MS; Saad Mir, MD; et al.
free access
JAMA Neurol. 2020;77(11):1366-1372. doi:10.1001/jamaneurol.2020.2730
This cohort study compares the rate of ischemic stroke among patients with COVID-19 vs patients with influenza in 2 hospitals in New York City, New York.
Terry E. Goldberg, PhD; Chen Chen, MS; Yuanjia Wang, PhD; et al.
free access
JAMA Neurol. 2020;77(11):1373-1381. doi:10.1001/jamaneurol.2020.2273
This meta-analysis seeks to determine if an episode of delirium is an independent risk factor for long-term cognitive decline.
Daniel Santos, MD; Mandip S. Dhamoon, MD, DrPH
free access
JAMA Neurol. 2020;77(11):1382-1389. doi:10.1001/jamaneurol.2020.2499
This cross-sectional study investigates the adequacy of blood pressure control among stroke survivors and antihypertensive treatment trends using National Health and Nutrition Examination Survey data.
Santosh B. Murthy, MD, MPH; Sung-Min Cho, DO; Ajay Gupta, MD, MS; et al.
free access
JAMA Neurol. 2020;77(11):1390-1397. doi:10.1001/jamaneurol.2020.2349
This meta-analysis evaluates which factors are associated with diffusion-weighted imaging lesions and whether these lesions are associated with functional outcomes among patients with intracerebral hemorrhage.
Nathaniel Lizak, MBBS; Charles B. Malpas, PhD; Sifat Sharmin, PhD; et al.
free access
JAMA Neurol. 2020;77(11):1398-1407. doi:10.1001/jamaneurol.2020.2453
This cohort study uses data from the MSBase international registry to examine the association of demographic and clinical factors, including the presence of relapses and exposure to immunotherapy, with the rate of disability accumulation in patients with secondary progressive multiple sclerosis.
Matthias Brendel, MD, MHBA; Henryk Barthel, MD, PhD; Thilo van Eimeren, MD; et al.
open access
JAMA Neurol. 2020;77(11):1408-1419. doi:10.1001/jamaneurol.2020.2526
This cross-sectional study investigates the potential of novel tau radiotracer 18F-PI-2620 as a biomarker in patients with clinically diagnosed progressive supranuclear palsy.
Divyanshu Dubey, MD; Michael R. Wilson, MD, MAS; Benjamin Clarkson, PhD; et al.
free access
has multimedia
JAMA Neurol. 2020;77(11):1420-1429. doi:10.1001/jamaneurol.2020.2231
This study describes expanding neurologic phenotype, cancer associations, outcomes, and immunopathologic features of Kelch-like protein-11 encephalitis.
-
Video:
Gait Ataxia in Autoimmune Kelch-like Protein 11 (KLHL11) Encephalitis
-
Video:
Nystagmus in Autoimmune Kelch-like Protein 11 (KLHL11) Encephalitis
-
Video:
Dysarthria in Autoimmune Kelch-like Protein 11 (KLHL11) Encephalitis
Christian Endisch, MD; Erik Westhall, PhD; Martin Kenda, MD; et al.
free access
JAMA Neurol. 2020;77(11):1430-1439. doi:10.1001/jamaneurol.2020.2340
This cohort study compares the parameters used for prognosis after cardiac arrest with the severity of hypoxic-ischemic encephalopathy shown on autopsy.